Log in
Enquire now
AVROBIO

AVROBIO

Developing gene therapies to potentially cure rare diseases.

OverviewStructured DataIssuesContributors

AVROBIO is a developer of clinical-stage lentiviral gene therapies for Fabry disease, Gaucher disease, and cystinosis, and developing therapies for Pompe disease.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Avrobio stock plunges after reporting clinical data for its AVR-RD-01 gene therapy to treat rare genetic Fabry disease

Uttara Choudhury

https://ca.proactiveinvestors.com/companies/news/206115/avrobio-stock-plunges-after-reporting-clinical-data-for-its-avr-rd-01-gene-therapy-to-treat-rare-genetic-fabry-disease-206115.html

Web

UHN Spin-out AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases & Cancer | TDC

Technology Development & Commercialization at UHN

http://tdc.uhnresearch.ca/content/uhn-spin-out-avrobio-inc-announces-25-million-series-financing-advance-novel-clinical-stage

Web

References

Find more companies like AVROBIO

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.